Eurizon SLJ Capital Ltd Buys Shares of 9,711 Medpace Holdings, Inc. $MEDP

Eurizon SLJ Capital Ltd bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 9,711 shares of the company’s stock, valued at approximately $5,454,000. Medpace accounts for 2.2% of Eurizon SLJ Capital Ltd’s investment portfolio, making the stock its 17th biggest position.

Other large investors also recently added to or reduced their stakes in the company. Optiver Holding B.V. acquired a new stake in Medpace during the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace during the 4th quarter valued at $30,000. Elyxium Wealth LLC acquired a new stake in Medpace during the 4th quarter valued at $30,000. Finally, Quarry LP purchased a new position in shares of Medpace during the 3rd quarter valued at $35,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the topic of several research analyst reports. Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. Truist Financial lowered their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $467.08.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Down 0.2%

Medpace stock opened at $447.11 on Friday. The company’s fifty day simple moving average is $457.47 and its 200-day simple moving average is $513.97. Medpace Holdings, Inc. has a 12 month low of $291.28 and a 12 month high of $628.92. The stock has a market cap of $12.77 billion, a P/E ratio of 28.10, a P/E/G ratio of 2.27 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.